
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is set to continue its successful growth trajectory, with the recent acquisition of Naveris and plans for expanding into the lucrative oncology market. As the market leader in transplant testing, the company has a strong financial outlook, and the potential for significant revenue through its upcoming AlloHeme test provides further upside. While potential risks from competition and pricing should be monitored, CDNA's demand for services and initiatives to improve revenue cycle management suggest continued success for the company.
Bears say
CareDx is projected to exceed its 2027 LR target of $500 million, due to expected strong performance in its core transplant business and the addition of a new MRD business. However, there may be challenges in meeting revenue expectations from its AlloSure Kidney and AlloMap Heart tests, and continued education efforts will be needed to drive adoption of these solutions in the market. While reliance on the Epic platform is expected to drive growth, it will also result in significant investments for the company.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares